A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Shimoni, Avichai
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. [electronic resource] - Cancer Oct 2012 - 4706-14 p. digital
Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
1097-0142
10.1002/cncr.27418 doi
Adult
Aged
Analysis of Variance
Antibodies, Monoclonal--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Carmustine--administration & dosage
Cytarabine--administration & dosage
Disease-Free Survival
Drug Administration Schedule
Early Termination of Clinical Trials
Etoposide--administration & dosage
Female
Humans
Lymphoma, Non-Hodgkin--drug therapy
Male
Melphalan--administration & dosage
Middle Aged
Odds Ratio
Prognosis
Proportional Hazards Models
Recurrence
Risk Factors
Sample Size
Stem Cell Transplantation
Survival Analysis
Transplantation Conditioning--methods
Transplantation, Autologous
Treatment Outcome
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. [electronic resource] - Cancer Oct 2012 - 4706-14 p. digital
Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
1097-0142
10.1002/cncr.27418 doi
Adult
Aged
Analysis of Variance
Antibodies, Monoclonal--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Carmustine--administration & dosage
Cytarabine--administration & dosage
Disease-Free Survival
Drug Administration Schedule
Early Termination of Clinical Trials
Etoposide--administration & dosage
Female
Humans
Lymphoma, Non-Hodgkin--drug therapy
Male
Melphalan--administration & dosage
Middle Aged
Odds Ratio
Prognosis
Proportional Hazards Models
Recurrence
Risk Factors
Sample Size
Stem Cell Transplantation
Survival Analysis
Transplantation Conditioning--methods
Transplantation, Autologous
Treatment Outcome